Cardio Diagnostics Holdings, Inc. (CDIO)
- Previous Close
4.5300 - Open
4.3300 - Bid 3.9000 x 100
- Ask --
- Day's Range
3.8000 - 4.4707 - 52 Week Range
3.7960 - 53.1000 - Volume
119,512 - Avg. Volume
46,948 - Market Cap (intraday)
6.953M - Beta (5Y Monthly) 3.65
- PE Ratio (TTM)
-- - EPS (TTM)
-9.3000 - Earnings Date May 19, 2025 - May 25, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
60.00
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, including concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
cdio.aiRecent News: CDIO
View MorePerformance Overview: CDIO
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CDIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CDIO
View MoreValuation Measures
Market Cap
6.87M
Enterprise Value
-298.58k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
101.49
Price/Book (mrq)
0.72
Enterprise Value/Revenue
20.34
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-69.36%
Return on Equity (ttm)
-133.96%
Revenue (ttm)
34.89k
Net Income Avi to Common (ttm)
-8.38M
Diluted EPS (ttm)
-9.3000
Balance Sheet and Cash Flow
Total Cash (mrq)
7.83M
Total Debt/Equity (mrq)
10.15%
Levered Free Cash Flow (ttm)
-2.41M